Studies using atherosclerosis models have demonstrated TREM2’s diverse roles: myeloid-specific TREM2 deletion reduces oxLDL uptake in foam cells and diminishes plaque progression—even in established lesions—independent of systemic inflammation or lipidemia. Here, TREM2 is linked to hyperlipidemia.